Citation Impact
Citing Papers
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
2013
The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice
2016
XBP1s Is an Anti-lipogenic Protein
2016
Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3
2015 Standout
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
2012
Microbiota in health and diseases
2022 Standout
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics
2021 Standout
The role of short chain fatty acids in appetite regulation and energy homeostasis
2015
Metagenomic analysis of gut microbiota modulatory effects of jujube (Ziziphus jujuba Mill.) polysaccharides in a colorectal cancer mouse model
2019 Standout
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
2017 Standout
Targeting autophagy in obesity: from pathophysiology to management
2018
Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
2017 Standout
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
Hepatic stellate cells as key target in liver fibrosis
2017
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
2012
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
2016
The coming of age of chaperone-mediated autophagy
2018
Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications
2013
Mechanisms of hepatic stellate cell activation
2017 Standout
Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review
2020 Standout
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Glucagon‐like peptide‐1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high‐fat diet in nonalcoholic steatohepatitis
2011
Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
2013 StandoutNature
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics
2020 Standout
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
2020 Standout
Hallmarks of aging: An expanding universe
2023 Standout
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
2019 Standout
Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases
2017
Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments
2014
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Obesity and inflammation: the linking mechanism and the complications
2016 Standout
Hepatocellular carcinoma
2021 Standout
Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
2011
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
2015
Pathophysiology of NASH: Perspectives for a Targeted Treatment
2013
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension
2014 Standout
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism
2016 Standout
Gut microbiome and health: mechanistic insights
2022 Standout
Bile Acid Signaling in Metabolic Disease and Drug Therapy
2014
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Hepatoprotective versus Oncogenic Functions of STAT3 in Liver Tumorigenesis
2011
Non-alcoholic fatty liver disease
2021 Standout
Leptin Promotes the Myofibroblastic Phenotype in Hepatic Stellate Cells by Activating the Hedgehog Pathway
2010
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
2013 Standout
Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs
2019
Dynamics and functions of lipid droplets
2018 Standout
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
2018 Standout
The role of short-chain fatty acids in microbiota–gut–brain communication
2019 Standout
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Adipocytokines and hepatic fibrosis
2015
Gut microbiota and Covid-19- possible link and implications
2020 Standout
Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of hepatocarcinogenesis in mice
2017
Therapeutic Landscape for NAFLD in 2020
2020
Molecular mechanisms of cancer development in obesity
2011
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis
2012
What We Talk About When We Talk About Fat
2014 Standout
Obesity and cancer: inflammation bridges the two
2016
Adiponectin Regulation and Function
2018
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
2014
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
2010
Diets link metabolic syndrome and colorectal cancer development
2017
Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice
2012
NAFLD: A multisystem disease
2015 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis
2011
Obesity and cancer—mechanisms underlying tumour progression and recurrence
2014
Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis
2017
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program
2012
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
2015
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients (LEAN ‐J )
2014
Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression
2011
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Cardiovascular Biology of the Incretin System
2012
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
Intestinal permeability – a new target for disease prevention and therapy
2014 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
2021
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
2015
Bile acids in glucose metabolism in health and disease
2018
Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research
2020 Standout
Pathophysiology of Type 2 Diabetes Mellitus
2020 Standout
Lipotoxicity and the gut-liver axis in NASH pathogenesis
2017
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
2012
The Role of Adiponectin in Cancer: A Review of Current Evidence
2012
The Liver under the Spotlight: Bile Acids and Oxysterols as Pivotal Actors Controlling Metabolism
2021
Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells
2011
Works of Jamie E. Mells being referenced
Adiponectin activation of AMPK disrupts leptin‐mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS‐3)
2010
Adiponectin Antagonizes the Oncogenic Actions of Leptin in Hepatocellular Carcinogenesis
2010
Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis
2014
GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
2011
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway
2010
The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
2013
Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis
2011
Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
2011
Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
2016
Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis
2014